These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 36502960)

  • 61. Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset.
    Hill MP; Bezard E; McGuire SG; Crossman AR; Brotchie JM; Michel A; Grimée R; Klitgaard H
    Mov Disord; 2003 Nov; 18(11):1301-5. PubMed ID: 14639671
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The selective mu-opioid receptor antagonist ADL5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in MPTP-lesioned macaque model of Parkinson's disease.
    Koprich JB; Fox SH; Johnston TH; Goodman A; Le Bourdonnec B; Dolle RE; DeHaven RN; DeHaven-Hudkins DL; Little PJ; Brotchie JM
    Mov Disord; 2011 Jun; 26(7):1225-33. PubMed ID: 21465551
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The monoamine re-uptake inhibitor UWA-101 improves motor fluctuations in the MPTP-lesioned common marmoset.
    Huot P; Johnston TH; Gandy MN; Reyes MG; Fox SH; Piggott MJ; Brotchie JM
    PLoS One; 2012; 7(9):e45587. PubMed ID: 23029119
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effects of (-)-sesamin on motor and memory deficits in an MPTP-lesioned mouse model of Parkinson's disease treated with l-DOPA.
    Zhao TT; Shin KS; Kim KS; Park HJ; Kim HJ; Lee KE; Lee MK
    Neuroscience; 2016 Dec; 339():644-654. PubMed ID: 27789382
    [TBL] [Abstract][Full Text] [Related]  

  • 65. L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease.
    Huot P; Johnston TH; Koprich JB; Fox SH; Brotchie JM
    Neuropharmacology; 2012 Oct; 63(5):829-36. PubMed ID: 22722022
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist.
    Iderberg H; Maslava N; Thompson AD; Bubser M; Niswender CM; Hopkins CR; Lindsley CW; Conn PJ; Jones CK; Cenci MA
    Neuropharmacology; 2015 Aug; 95():121-9. PubMed ID: 25749357
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Adenosine A₂A-receptor antagonist istradefylline enhances the motor response of L-DOPA without worsening dyskinesia in MPTP-treated common marmosets.
    Uchida S; Tashiro T; Kawai-Uchida M; Mori A; Jenner P; Kanda T
    J Pharmacol Sci; 2014; 124(4):480-5. PubMed ID: 24681641
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Striatal leucine-rich repeat kinase 2 mRNA is increased in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned common marmosets (Callithrix jacchus) with L-3, 4-dihydroxyphenylalanine methyl ester-induced dyskinesia.
    Hurley MJ; Patel PH; Jackson MJ; Smith LA; Rose S; Jenner P
    Eur J Neurosci; 2007 Jul; 26(1):171-7. PubMed ID: 17614947
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Regulation of cortical and striatal 5-HT1A receptors in the MPTP-lesioned macaque.
    Huot P; Johnston TH; Koprich JB; Winkelmolen L; Fox SH; Brotchie JM
    Neurobiol Aging; 2012 Jan; 33(1):207.e9-19. PubMed ID: 21051107
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys.
    Morin N; Grégoire L; Gomez-Mancilla B; Gasparini F; Di Paolo T
    Neuropharmacology; 2010 Jun; 58(7):981-6. PubMed ID: 20074579
    [TBL] [Abstract][Full Text] [Related]  

  • 71. An evaluation of istradefylline treatment on Parkinsonian motor and cognitive deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque models.
    Ko WKD; Camus SM; Li Q; Yang J; McGuire S; Pioli EY; Bezard E
    Neuropharmacology; 2016 Nov; 110(Pt A):48-58. PubMed ID: 27424102
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).
    Pearce RK; Jackson M; Smith L; Jenner P; Marsden CD
    Mov Disord; 1995 Nov; 10(6):731-40. PubMed ID: 8749992
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias.
    Riahi G; Morissette M; Parent M; Di Paolo T
    Eur J Neurosci; 2011 May; 33(10):1823-31. PubMed ID: 21501255
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A preclinical study on the combined effects of repeated eltoprazine and preladenant treatment for alleviating L-DOPA-induced dyskinesia in Parkinson's disease.
    Ko WKD; Li Q; Cheng LY; Morelli M; Carta M; Bezard E
    Eur J Pharmacol; 2017 Oct; 813():10-16. PubMed ID: 28739086
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Further characterisation of psychosis-like behaviours induced by L-DOPA in the MPTP-lesioned marmoset.
    Kwan C; Nuara SG; Gourdon JC; Huot P
    Naunyn Schmiedebergs Arch Pharmacol; 2021 Aug; 394(8):1685-1692. PubMed ID: 33963876
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A positive allosteric modulator of mGlu4 receptors restores striatal plasticity in an animal model of l-Dopa-induced dyskinesia.
    Calabrese V; Picconi B; Heck N; Campanelli F; Natale G; Marino G; Sciaccaluga M; Ghiglieri V; Tozzi A; Anceaume E; Cuoc E; Caboche J; Conquet F; Calabresi P; Charvin D
    Neuropharmacology; 2022 Nov; 218():109205. PubMed ID: 35940348
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation.
    Smith LA; Tel BC; Jackson MJ; Hansard MJ; Braceras R; Bonhomme C; Chezaubernard C; Del Signore S; Rose S; Jenner P
    Mov Disord; 2002 Sep; 17(5):887-901. PubMed ID: 12360537
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Pridopidine, a clinic-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques.
    Johnston TH; Geva M; Steiner L; Orbach A; Papapetropoulos S; Savola JM; Reynolds IJ; Ravenscroft P; Hill M; Fox SH; Brotchie JM; Laufer R; Hayden MR
    Mov Disord; 2019 May; 34(5):708-716. PubMed ID: 30575996
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [TBL] [Abstract][Full Text] [Related]  

  • 80. L-745,870 reduces the expression of abnormal involuntary movements in the 6-OHDA-lesioned rat.
    Huot P; Johnston TH; Koprich JB; Espinosa MC; Reyes MG; Fox SH; Brotchie JM
    Behav Pharmacol; 2015 Feb; 26(1-2):101-8. PubMed ID: 25303957
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.